In an unexpected turn of events, Apple is set to release its highly anticipated Apple Watch Series 9 and Apple Watch Ultra 2 without their blood oxygen features. The decision comes on the heels of a federal appeals court ruling that bars Apple from importing wearables with this specific feature into the United States. The ban is a result of an ongoing legal battle between Apple and Masimo Corporation, along with Cercacor Laboratories, who claim that the devices infringe on their patents.
Legal Battle Unfolds: USITC Finds Apple Guilty of Patent Infringement
The controversy began with the U.S. International Trade Commission (USITC) finding that Apple had infringed on two patents owned by Masimo Corporation and Cercacor Laboratories. The patents in question, according to the commission’s decision finalized on December 26, led to the ban on importing wearables with the blood oxygen feature. Apple, not willing to accept defeat, appealed the decision and sought to extend a stay that would allow the import of these devices during the appeal process. However, the federal appeals court ruled against Apple’s request, prompting the tech giant to make a swift decision regarding the release of its latest watches.
In response to the legal setback, Apple announced that the Apple Watch Series 9 and Apple Watch Ultra 2 without the blood oxygen feature would be available for purchase from Apple’s official website starting at 6 am on January 18. The watches will also be on sale in Apple Stores from the same date. The move is a strategic one by Apple, ensuring that customers can still access their products despite the limitations imposed by the court ruling.
Dueling Perspectives: Masimo Celebrates Victory, Apple Disagrees with USITC Decision
Masimo’s founder and CEO, Joe Kiani, expressed satisfaction with the court ruling, stating that it affirms the importance of respecting the intellectual rights of inventors. Kiani emphasized that even tech giants like Apple must face consequences when found guilty of patent infringement. On the flip side, Apple expressed strong disagreement with the USITC decision and the resulting ban. In its official statement, the company maintained its stance that it would continue to fight the allegations. Apple is taking steps to comply with the ruling while minimizing disruption for its customers, including introducing a version of the watches without the blood oxygen feature.
The Future of Apple Watches Amidst Legal Challenges
As Apple navigates this legal obstacle, the question arises: what does the future hold for the company’s smartwatches? The absence of the blood oxygen feature in the Series 9 and Ultra 2 watches raises concerns among consumers who may have been eagerly anticipating this health-monitoring capability. Apple, known for its innovation and commitment to user experience, will undoubtedly continue to explore legal avenues to overturn the USITC decision. Meanwhile, users who have already purchased Apple Watches with the blood oxygen feature need not worry, as Apple reassures them that there will be no impact on previously purchased units.
The Apple Watch Series 9 and Apple Watch Ultra 2 will be hitting the shelves without a key health-monitoring feature due to the ongoing legal battle with Masimo Corporation and Cercacor Laboratories. The outcome of this dispute may shape the future landscape of wearable technology, emphasizing the delicate balance between innovation and the protection of intellectual property rights. As Apple continues to adapt to the challenges posed by the court ruling, consumers will be closely watching how the tech giant navigates these legal waters while maintaining its commitment to delivering cutting-edge products.
Read about Apple’s Vision Pro Finally Gets a Release Date of Feb…
